Buntaro Fujita1, Stephan Ensminger1, Timm Bauer2, Helge Möllmann3, Andreas Beckmann4, Raffi Bekeredjian5, Sabine Bleiziffer6, Elke Schäfer7, Christian W Hamm8, Friedrich W Mohr9, Hugo A Katus5, Wolfgang Harringer10, Thomas Walther11, Christian Frerker12. 1. Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany. 2. Department of Cardiology, University of Giessen, Giessen, Germany. 3. Department of Internal Medicine, St.-Johannes-Hospital, Dortmund, Germany. 4. German Society of Thoracic, Cardiac and Vascular Surgery, Berlin, Germany. 5. Department of Cardiology, University of Heidelberg, Heidelberg, Germany. 6. Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany. 7. BQS Institute for Quality and Patient Safety, Düsseldorf, Germany. 8. Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany. 9. Department of Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Leipzig, Germany. 10. Department of Thoracic and Cardiovascular Surgery, Klinikum Braunschweig, Braunschweig, Germany. 11. Department of Cardiac Surgery, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany. 12. Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.
Abstract
OBJECTIVES: Surgical aortic valve replacement (sAVR) is coming under close scrutiny with the recent upswing in the use of less invasive approaches. The aim of this analysis was to identify current trends in patient selection, procedural characteristics and outcomes after sAVR in Germany. METHODS: We analysed data from 42 776 patients included in the German Aortic Valve Registry who underwent sAVR with and without coronary artery bypass surgery (CABG) between 2011 and 2015. Baseline, procedural and short-term outcome parameters were analysed. RESULTS: Of all registered patients, 26 618 (62.2%) underwent isolated sAVR and 16 158 (37.8%) sAVR + CABG. The median age was 72 years, and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) was 2.3%. From 2011 to 2015, there was a decline in STS PROM (2.4-2.2%, P < 0.001) and a decline in risk factors, such as pulmonary hypertension (9.1-3.2%, P < 0.001), occlusive arterial disease (19.6-17.7%, P = 0.003), mitral regurgitation ≥2° (10.6-7.6%, P < 0.001) and New York Heart Association Class III/IV (65.3-59.2%, P < 0.001). In-hospital mortality was 2.3%, 1.3% had disabling stroke, 0.4% residual aortic regurgitation ≥2°, and the incidence of new-onset pacemaker/implantable cardioverter-defibrillator implantation was 3.9%. There was an increase in the use of biological valves in patients <65 years (50.1-65.7%, P < 0.001), and the proportion of rapid deployment valves increased significantly (1.5-8.4%, P < 0.001) over the investigated time period. CONCLUSIONS: Both isolated sAVR as well as sAVR + CABG resulted in excellent in-hospital outcomes based on >42 000 patients treated between 2011 and 2015. The implementation of alternative treatment strategies has resulted in palpable changes in patient and device selection.
OBJECTIVES: Surgical aortic valve replacement (sAVR) is coming under close scrutiny with the recent upswing in the use of less invasive approaches. The aim of this analysis was to identify current trends in patient selection, procedural characteristics and outcomes after sAVR in Germany. METHODS: We analysed data from 42 776 patients included in the German Aortic Valve Registry who underwent sAVR with and without coronary artery bypass surgery (CABG) between 2011 and 2015. Baseline, procedural and short-term outcome parameters were analysed. RESULTS: Of all registered patients, 26 618 (62.2%) underwent isolated sAVR and 16 158 (37.8%) sAVR + CABG. The median age was 72 years, and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) was 2.3%. From 2011 to 2015, there was a decline in STS PROM (2.4-2.2%, P < 0.001) and a decline in risk factors, such as pulmonary hypertension (9.1-3.2%, P < 0.001), occlusive arterial disease (19.6-17.7%, P = 0.003), mitral regurgitation ≥2° (10.6-7.6%, P < 0.001) and New York Heart Association Class III/IV (65.3-59.2%, P < 0.001). In-hospital mortality was 2.3%, 1.3% had disabling stroke, 0.4% residual aortic regurgitation ≥2°, and the incidence of new-onset pacemaker/implantable cardioverter-defibrillator implantation was 3.9%. There was an increase in the use of biological valves in patients <65 years (50.1-65.7%, P < 0.001), and the proportion of rapid deployment valves increased significantly (1.5-8.4%, P < 0.001) over the investigated time period. CONCLUSIONS: Both isolated sAVR as well as sAVR + CABG resulted in excellent in-hospital outcomes based on >42 000 patients treated between 2011 and 2015. The implementation of alternative treatment strategies has resulted in palpable changes in patient and device selection.
Authors: Sami Kueri; Fabian A Kari; Rafael Ayala Fuentes; Hans-Hinrich Sievers; Friedhelm Beyersdorf; Wolfgang Bothe Journal: Dtsch Arztebl Int Date: 2019-06-21 Impact factor: 5.594
Authors: Paolo Berretta; Luca Montecchiani; Fabio Vagnarelli; Mariano Cefarelli; Jacopo Alfonsi; Carlo Zingaro; Filippo Capestro; Michele D Pierri; Alessandro D'alfonso; Marco Di Eusanio Journal: Ann Cardiothorac Surg Date: 2020-09
Authors: Ana López-de-Andrés; Napoleon Perez-Farinos; Javier de Miguel-Díez; Valentín Hernández-Barrera; Manuel Méndez-Bailón; José M de Miguel-Yanes; Rodrigo Jiménez-García Journal: Cardiovasc Diabetol Date: 2018-10-16 Impact factor: 9.951
Authors: Rodrigo Jiménez-García; Napoleón Perez-Farinos; Javier de Miguel-Díez; Valentín Hernández-Barrera; Manuel Méndez-Bailón; Isabel Jimenez-Trujillo; José M de Miguel-Yanes; Ana López-de-Andrés Journal: Braz J Cardiovasc Surg Date: 2020-02-01
Authors: Martin Andreas; Paolo Berretta; Marco Solinas; Giuseppe Santarpino; Utz Kappert; Antonio Fiore; Mattia Glauber; Martin Misfeld; Carlo Savini; Elisa Mikus; Emmanuel Villa; Kevin Phan; Theodor Fischlein; Bart Meuris; Gianluca Martinelli; Kevin Teoh; Carmelo Mignosa; Malakh Shrestha; Thierry P Carrel; Tristan Yan; Guenther Laufer; Marco Di Eusanio Journal: Eur J Cardiothorac Surg Date: 2020-11-01 Impact factor: 4.191